ETS1 and breast carcinoma: The effectiveness of PARPi in only Ets‐1 expressing breast cancer cells lead us to suggest that Ets‐1 expression may represent a biomarker potentially able to identify the most sensitive breast cancer cells for treatment with PARPi.